Post by Animedix, Inc

Welcome to Medronome: The Science of Therapeutic Timing—a new Animedix series exploring a simple but transformative idea: Biologic signals are rarely binary. They are governed by time. In our inaugural vignette, we begin with a clinical puzzle familiar to every oncologist: a patient with KRAS-mutant lung cancer initially responds dramatically to targeted therapy—only to relapse months later. The answer may lie not only in genetics, but in the timing of cellular signaling. This episode explores how RAS signaling kinetics, sustained pathway activation, and kinetic filtering shape cancer biology and therapeutic resistance. Because cells do not simply ask, "Is a signal present?" They ask, "How long did it last?" Welcome to the Medronome. Because in medicine, timing is biology. Interested in the future of RAS-targeted therapeutics? We encourage you to explore the exciting work being pursued by innovators across the field, including teams at @Revolution Medicines, @Amgen, and @Bristol Myers Squibb, who are advancing our understanding of RAS biology and helping redefine what may be possible for patients with cancer. #Medronome #TheScienceOfTherapeuticTiming #Animedix #PrecisionMedicine #KRAS #RAS #RASInhibitors #KRASG12C #Oncology #NSCLC #LungCancer #CancerResearch #SignalTransduction #SystemsBiology #PrecisionOncology #TargetedTherapy #TranslationalMedicine #MedicalEducation #ScienceEducation #CancerBiology #AdaptiveResistance #MAPK #RevolutionMedicines #Amgen #BristolMyersSquibb

Video Content